• +1-646-491-9876
    • +91-20-67278686

    Search

    Leishmaniasis (Kala-Azar) Pipeline Review H1 2017

    Leishmaniasis (Kala-Azar) Pipeline Review H1 2017

    • Report Code ID: RW0001799280
    • Category Pharmaceuticals
    • No. of Pages 97
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2017, provides an overview of the Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline landscape.

    Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 3, 11, 8 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 10 and 9 molecules, respectively.

    Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar) (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Leishmaniasis (Kala-Azar) - Overview
    Leishmaniasis (Kala-Azar) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Leishmaniasis (Kala-Azar) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development
    Advinus Therapeutics Ltd
    BioLingus AG
    Daiichi Sankyo Company Ltd
    iCo Therapeutics Inc.
    Laboratorios LETI SL
    ManRos Therapeutics
    Matinas BioPharma Holdings Inc
    Nanomerics Ltd
    Novartis AG
    Oblita Therapeutics BVBA
    Leishmaniasis (Kala-Azar) - Drug Profiles
    (gentamicin sulfate + paromomycin sulfate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    18-MC - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    amphotericin B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    amphotericin B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    amphotericin B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    amphotericin B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Amphotericin B sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    candicidin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CDRI-99288 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    D-121 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GNF-6702 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    hypoestoxide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    interferon gamma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KVH-14 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    leishmaniasis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    leishmaniasis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    leishmaniasis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    leishmaniasis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    leishmaniasis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NPC-1161B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    P-MAPA - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptides for Infectious Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-015-2344 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Leishmaniasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Leishmaniasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Visceral Leishmaniasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Infectious Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Infectious Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Leishmaniasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Leishmaniasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Leishmaniasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Leishmaniasis and Chagas Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Visceral Leishmaniasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Visceral Leishmaniasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize CD206 for Leishmaniasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease, Leishmaniasis and African Trypanosomiasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Leishmania Major Casein Kinase 1 Isoform 2 for Leishmaniasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit LHR1 for Leishmaniasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Nucleoside Hydrolase for Leishmaniasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptides for Infectious Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Leishmaniasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    visceral leishmaniasis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Leishmaniasis (Kala-Azar) - Dormant Projects
    Leishmaniasis (Kala-Azar) - Discontinued Products
    Leishmaniasis (Kala-Azar) - Product Development Milestones
    Featured News & Press Releases
    Nov 28, 2016: iCo Therapeutics Announces Positive Study Results and Significant Advances related to Oral Amphotericin B Program
    Aug 08, 2016: A single compound could treat three parasitic diseases
    Dec 15, 2015: U.S. Issues Patent on Corifungin
    Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program
    Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions
    Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients
    Feb 26, 2013: National Institutes of Health Supports Acea's Research
    Mar 06, 2012: £10 million boost for neglected tropical disease research at Dundee
    Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis
    Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS
    Jul 01, 2011: FDA issues orphan-drug designation to Corifungin
    Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status
    Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC
    Dec 14, 2005: Collaboration on the Development of Anti-Parasitic Drugs for Both Malaria and Leishmaniasis
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Leishmaniasis (Kala-Azar) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Leishmaniasis (Kala-Azar) - Pipeline by Advinus Therapeutics Ltd, H1 2017
    Leishmaniasis (Kala-Azar) - Pipeline by BioLingus AG, H1 2017
    Leishmaniasis (Kala-Azar) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc., H1 2017
    Leishmaniasis (Kala-Azar) - Pipeline by Laboratorios LETI SL, H1 2017
    Leishmaniasis (Kala-Azar) - Pipeline by ManRos Therapeutics, H1 2017
    Leishmaniasis (Kala-Azar) - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
    Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, H1 2017
    Leishmaniasis (Kala-Azar) - Pipeline by Novartis AG, H1 2017
    Leishmaniasis (Kala-Azar) - Pipeline by Oblita Therapeutics BVBA, H1 2017
    Leishmaniasis (Kala-Azar) - Dormant Projects, H1 2017
    Leishmaniasis (Kala-Azar) - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Leishmaniasis (Kala-Azar) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Leishmaniasis (Kala-Azar) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Advinus Therapeutics Ltd
    BioLingus AG
    Daiichi Sankyo Company Ltd
    iCo Therapeutics Inc.
    Laboratorios LETI SL
    ManRos Therapeutics
    Matinas BioPharma Holdings Inc
    Nanomerics Ltd
    Novartis AG
    Oblita Therapeutics BVBA

    Request for Sample

    Report Url http://www.reportsweb.com//leishmaniasis-kala-azar-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//leishmaniasis-kala-azar-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//leishmaniasis-kala-azar-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments